Afatinib Dose Adjustment Improves Tolerability Without Affecting Efficacy in NSCLC

Share this content:
Dose adjustments of afatinib among patients with NSCLC appear to reduce the incidence and severity of treatment-related adverse events.
Dose adjustments of afatinib among patients with NSCLC appear to reduce the incidence and severity of treatment-related adverse events.

Dose adjustments of afatinib among patients with advanced non-small cell lung cancer (NSCLC) appear to reduce the incidence and severity of treatment-related adverse events without negatively affecting efficacy, according to a post-hoc analysis of the LUX-Lung 3 and LUX-Lung 6 trials.1

Dose reductions, which occurred mostly within the first 6 months of treatment, were associated with decreases in the incidence and severity of treatment-related adverse events.

Median progression-free survival was similar between those who had a dose reduction within the first 6 months and those who did not.

These findings may provide clinicians and patients with confidence when reducing the dose of afatinib to address treatment-related adverse events.

The multicenter, open-label, phase 3 LUX-Lung 3 and LUX-Lung 6 trials evaluated the efficacy and safety of first-line afatinib, compared with that of chemotherapy, among patients with EGFR mutation-positive, advanced NSCLC.

RELATED: Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?

Both studies demonstrated a significant improvement in progression-free survival, lung cancer-related symptoms, and quality of life with afatinib.

Reference

  1. New analysis showed dose adjustment of Giotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer [press release]. Boehringer Ingelheim website. https://www.boehringer-ingelheim.com/press-release/new-analysis-showed-dose-adjustment-giotrif-afatinib-improved-tolerability. Updated September 8, 2016. Accessed September 9, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters